 BOSTON and LONDON, Nov. 19, 2020 GLOBE NEWSWIRE -- Orchard Therapeutics Nasdaq: ORTX, a global gene therapy leader, today announced that the U.S. Food and Drug Administration FDA has cleared the companys Investigational New Drug IND application for OTL-200, an autologous, hematopoietic stem cell, lentiviral vector-based gene therapy in development for the treatment of metachromatic leukodystrophy MLD. The company also has applied for Regenerative Medicine Advanced Therapy RMAT designation for OTL-200 to help facilitate additional dialogue with the FDA on this important therapy. 